Tropé CG - Search Results

1

Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer.

Makar AP, Tropé CG, Tummers P, Denys H, Vandecasteele K. Makar AP, et al. Among authors: trope cg. Oncologist. 2016 Jun;21(6):745-54. doi: 10.1634/theoncologist.2015-0239. Epub 2016 Mar 23. Oncologist. 2016. PMID: 27009938 Free PMC article. Review.

2

Endometrial and ovarian malignancies: epidemiology, etiology and prognostic factors.

Makar AP, Tropé CG. Makar AP, et al. Among authors: trope cg. Acta Obstet Gynecol Scand. 1992 Jul;71(5):331-6. doi: 10.3109/00016349209021068. Acta Obstet Gynecol Scand. 1992. PMID: 1355947 Review. No abstract available.

3

Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis.

Makar AP, Kristensen GB, Kaern J, Børmer OP, Abeler VM, Tropé CG. Makar AP, et al. Among authors: trope cg. Obstet Gynecol. 1992 Jun;79(6):1002-10. Obstet Gynecol. 1992. PMID: 1579296

4

CA 125 measured before second-look laparotomy is an independent prognostic factor for survival in patients with epithelial ovarian cancer.

Makar AP, Kristensen GB, Børmer OP, Tropé CG. Makar AP, et al. Among authors: trope cg. Gynecol Oncol. 1992 Jun;45(3):323-8. doi: 10.1016/0090-8258(92)90313-8. Gynecol Oncol. 1992. PMID: 1612511

5

Gynecologic malignancy and surgery: from quantity to quality of life.

Makar AP, Tropé CG. Makar AP, et al. Among authors: trope cg. Curr Opin Obstet Gynecol. 1992 Jun;4(3):419-29. Curr Opin Obstet Gynecol. 1992. PMID: 1623153 Review.

6

Epidemiology, etiology, screening, prevention, and diagnosis in female genital cancer.

Tropé CG, Makar AP. Tropé CG, et al. Curr Opin Oncol. 1991 Oct;3(5):908-19. doi: 10.1097/00001622-199110000-00016. Curr Opin Oncol. 1991. PMID: 1751582 Review.

7

The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer.

Makar AP, Baekelandt M, Tropé CG, Kristensen GB. Makar AP, et al. Among authors: trope cg. Gynecol Oncol. 1995 Feb;56(2):175-80. doi: 10.1006/gyno.1995.1027. Gynecol Oncol. 1995. PMID: 7896181

8

Is serum CA 125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer?

Makar AP, Kristensen GB, Børmer OP, Tropé CG. Makar AP, et al. Among authors: trope cg. Gynecol Oncol. 1993 Apr;49(1):3-7. doi: 10.1006/gyno.1993.1076. Gynecol Oncol. 1993. PMID: 8482556

9

Serum CA 125 level allows early identification of nonresponders during induction chemotherapy.

Makar AP, Kristensen GB, Børmer OP, Tropé CG. Makar AP, et al. Among authors: trope cg. Gynecol Oncol. 1993 Apr;49(1):73-9. doi: 10.1006/gyno.1993.1089. Gynecol Oncol. 1993. PMID: 8482563

10

Surgery for borderline tumor of the ovary.

Tropé CG, Kristensen G, Makar A. Tropé CG, et al. Semin Surg Oncol. 2000 Jul-Aug;19(1):69-75. doi: 10.1002/1098-2388(200007/08)19:1<69::aid-ssu11>3.0.co;2-e. Semin Surg Oncol. 2000. PMID: 10883027 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

441 results

Search Page